Retapamulin

Publication Details

Estimated reading time: 1 minute

CASRN: 224452-66-8

image 135218278 in the ncbi pubchem database

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of retapamulin during breastfeeding. Because retapamulin is poorly absorbed after topical application, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants after maternal application away from the breast. Only water-miscible cream or gel products should be applied to the breast, because ointments may expose the infant to high levels of mineral paraffins via licking.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Noti A, Grob K, Biedermann M, et al. Exposure of babies to C(15)-C(45) mineral paraffins from human milk and breast salves. Regul Toxicol Pharmacol. 2003;38:317–25. [PubMed: 14623482]

Substance Identification

Substance Name

Retapamulin

CAS Registry Number

224452-66-8

Drug Class

Breast Feeding

Lactation

Milk, Human

Anti-Infective Agents, Local

Anti-Bacterial Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.